



Eastern European Breast Cancer Update

8-10 April 2010, Prague
Andel's Hotel



Eastern European Breast Cancer Update

CONFIRMED FACULTY

Co-Chairs

Day 1

John Crown, MD

St Vincent's Hospital
Dublin, Ireland

Vladimir Semiglazov, MD

NN Petrov Research Institute of
Oncology
St Petersburg, Russia

Day 2

Sunil Verma, MD

Toronto Sunnybrook Regional
Cancer Center
Toronto, Ontario, Canada

Faculty

Giuseppe Curigliano, MD, PhD

European Institute of Oncology
Milan, Italy

John Pippen, MD

US Oncology
Baylor Sammons Cancer Center
Dallas, Texas, United States

N. N. Semenov, MD

Blokhin Cancer Research Center
Moscow, Russia

Marina Stenina, MD

Blokhin Cancer Research Center
Moscow, Russia

MEETING VENUE

Andel's Hotel
Stroupeznickeho 21
Prague, Czech Republic

prIME Oncology's Eastern European Breast Cancer Update is a 1.5-day educational activity for Eastern European and Russian delegates. The meeting will focus on updates in breast cancer management and will include highlights from the 2009 San Antonio Breast Cancer Symposium (SABCS), the 4th International Breast Cancer Conference (IBCC4), and the 7th European Breast Cancer Conference (EBCC7). The format of the meeting features standard didactic presentations, interactive clinical cases, and clinical opinion poll questions. "Ask the Experts" sessions will give attendees the opportunity to pose questions to international breast cancer experts. This approach will allow for a highly interactive environment in which physicians can update their knowledge on breast cancer therapies and enhance decision-making capabilities in this area.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

- Analyze the role of anthracycline-based regimens in patients with early breast cancer, including optimal patient selection and management of side effects
- Identify novel therapeutic agents that may be used in the adjuvant and neoadjuvant settings to further improve patient outcomes
- Describe the role of molecular profiling in breast cancer, and discuss how these profiles guide choice of therapy
- Analyze the latest clinical research on systemic therapy for patients with metastatic triple-negative breast cancer
- Review the results of recent clinical trials focusing on the addition of anti-angiogenic therapy to standard treatment for metastatic breast cancer
- Summarize emerging data for novel therapeutic agents that may be used in patients who have had disease progression following standard chemotherapy
- Evaluate and select optimal treatment strategies for the management of HER2-positive breast cancer
- Outline appropriate treatment options for the management of locally advanced, endocrine-responsive breast cancer
- Identify the potential effects of economic limitations on current treatment guidelines for breast cancer

8-10 April 2010, Prague, Czech Republic

AGENDA

Friday, 9 April 2010

09.00 Welcome and demographics
John Crown, MD
Vladimir Semiglazov, MD

09.15 Clinical opinion poll question

09.25 The role of nonanthracycline-based chemotherapy regimens in the adjuvant setting
Marina Stenina, MD
Faculty commentary

09.55 Clinical opinion poll question

10.05 Can the benefits of adjuvant systemic therapy for HER2-negative breast cancer be further improved?
John Crown, MD
Faculty commentary

10.35 Ask the experts

10.55 Break

11.15 Clinical opinion poll question

11.25 Breast cancer molecular profiling as a guide to treatment planning
Sunil Verma, MD
Commentary: Giuseppe Curigliano, MD, PhD

12.05 Clinical opinion poll question

12.15 Triple-negative breast cancer: Current therapeutic strategies and future directions
John Pippen, MD
Faculty commentary

12.45 Ask the experts

13.00 Lunch

14.00 Clinical opinion poll question

14.10 Strategies for improving outcomes in HER2-negative metastatic breast cancer
Giuseppe Curigliano, MD, PhD
Faculty commentary

14.40 Clinical opinion poll question

14.50 HER2-amplified metastatic breast cancer: Optimal management of disease progression during trastuzumab therapy
Sunil Verma, MD
Faculty commentary

15.20 Ask the experts

15.40 Concluding remarks and review of Day 2 agenda
John Crown, MD
Vladimir Semiglazov, MD



Eastern European Breast Cancer Update

8-10 April 2010, Prague, Czech Republic

Saturday, 10 April 2010

- 09.00** Economic realities: Their impact on practice guidelines in oncology
Vladimir Semiglazov, MD
Faculty commentary
- 09.30** Interactive Clinical Case #1
Early breast cancer: Optimizing outcomes of adjuvant therapy
Sunil Verma, MD
- 10.00** Panel discussion
- 10.10** Interactive Clinical Case #2
Management of locally advanced, endocrine-responsive breast cancer
Parts I & II: Vladimir Semiglazov, MD
Part III & IV: N. N. Semenov, MD
- 10.40** Panel discussion
- 10.50** Ask the experts
- 11.10** Break
- 11.30** Interactive Clinical Case #3
Targeted therapy for HER2-overexpressing metastatic breast cancer
Giuseppe Curigliano, MD, PhD
- 12.00** Panel discussion
- 12.10** Interactive Clinical Case #4
Current management of recurrent triple-negative breast cancer: What's the best approach?
John Pippin, MD
- 12.40** Panel discussion
- 12.50** Ask the experts
- 13.10** Concluding remarks
Sunil Verma, MD

Meeting Venue

Andel's Hotel
Stroupeznického 21
Prague, Czech Republic

To register, please visit our Website
www.prIMEoncology.org

DEADLINE for registration:
26 March 2010

For more information and hotel accommodation reservation, please visit www.prIMEoncology.org or contact Wendy Krijnen at wendy.krijnen@prIMEoncology.org
☎ +31 70 3067 194